Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 839 articles:
HTML format



Single Articles


    July 2021
  1. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    PubMed    


  2. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    PubMed     Abstract available


  3. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


  4. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    PubMed     Abstract available


  5. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    PubMed     Abstract available


  6. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    PubMed     Abstract available


  7. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    PubMed    


  8. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    PubMed     Abstract available


  9. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    PubMed     Abstract available


  10. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    PubMed     Abstract available


  11. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    PubMed     Abstract available


  12. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    PubMed     Abstract available


  13. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    PubMed     Abstract available


  14. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    PubMed     Abstract available


  15. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    PubMed     Abstract available


  16. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    PubMed     Abstract available


  17. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    PubMed    


    June 2021
  18. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  19. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  20. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    PubMed     Abstract available


  21. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    PubMed     Abstract available


  22. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    PubMed     Abstract available


  23. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    PubMed    


  24. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    PubMed    


  25. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    PubMed    


    May 2021
  26. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed     Abstract available


  27. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    PubMed    


  28. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    PubMed    


  29. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    PubMed    


  30. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    PubMed     Abstract available


  31. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    PubMed     Abstract available


  32. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    PubMed     Abstract available


  33. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  34. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    PubMed     Abstract available


  35. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    PubMed     Abstract available


  36. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    PubMed     Abstract available


  37. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


  38. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    PubMed     Abstract available


    April 2021
  39. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    PubMed    


  40. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    PubMed     Abstract available


  41. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    PubMed    


  42. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    PubMed     Abstract available


  43. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    PubMed    


  44. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    PubMed     Abstract available


  45. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    PubMed     Abstract available


  46. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    PubMed    


  47. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    PubMed    


  48. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    PubMed    


  49. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    PubMed    


    March 2021
  50. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available


  51. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    PubMed     Abstract available


  52. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    PubMed    


  53. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    PubMed     Abstract available


  54. HARRISON SA, Gawrieh S, Roberts K, Lisanti CJ, et al
    Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00176.
    PubMed     Abstract available


  55. AN YA, Chen S, Deng Y, Wang ZV, et al
    The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00174.
    PubMed     Abstract available


  56. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    PubMed    


  57. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    PubMed    


  58. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    PubMed     Abstract available


  59. GEIDL-FLUECK B, Hochuli M, Nemeth A, Eberl A, et al
    Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.
    J Hepatol. 2021 Mar 5. pii: S0168-8278(21)00161.
    PubMed     Abstract available


  60. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" (J Hepatol [2020] 505-515).
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00103.
    PubMed    


  61. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    PubMed    


  62. WANG J, Liu D, Qi X
    A step forward to predict the risk of post-hepatectomy portal hypertension.
    J Hepatol. 2021 Mar 2. pii: S0168-8278(21)00159.
    PubMed    


  63. MEIJNIKMAN AS, Bruin S, Groen AK, Nieuwdorp M, et al
    Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD.
    J Hepatol. 2021;74:748-749.
    PubMed    


  64. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    PubMed     Abstract available


    February 2021
  65. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    


  66. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  67. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    PubMed     Abstract available


  68. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  69. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    


  70. HARRISON SA, Bashir MR, Lee KJ, Shim-Lopez J, et al
    A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Feb 10. pii: S0168-8278(21)00099.
    PubMed     Abstract available


  71. LIANG B, Zhou Y, Qian M, Xu M, et al
    TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00095.
    PubMed     Abstract available


  72. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    PubMed     Abstract available


  73. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  74. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    PubMed    


  75. GUPTA P, Soundararajan R, Patel A, Kumar-M P, et al
    Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00091.
    PubMed     Abstract available


  76. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available


  77. MUSHTAQ K, Khan MU, Iqbal F, Alsoub DH, et al
    NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.
    J Hepatol. 2021;74:482-484.
    PubMed    


  78. JI D, Cheng G, Lau G
    Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
    J Hepatol. 2021;74:484-485.
    PubMed    


    January 2021
  79. SONG Q, Wang J, Griffiths A, Song Z, et al
    Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development".
    J Hepatol. 2021 Jan 30. pii: S0168-8278(21)00083.
    PubMed    


  80. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00003.
    PubMed    


  81. WU X, Poulsen KL, Sanz-Garcia C, Huang E, et al
    Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)".
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00014.
    PubMed    


  82. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    PubMed    


  83. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    PubMed    


  84. LONG J, Bian J, Zhao H
    Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00019.
    PubMed    


  85. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    PubMed     Abstract available


  86. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    PubMed     Abstract available


  87. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    PubMed    


  88. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    PubMed    


    December 2020
  89. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    PubMed    


  90. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    PubMed    


  91. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    PubMed    


  92. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    PubMed    


  93. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    PubMed    


  94. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    PubMed    


  95. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    PubMed    


  96. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    PubMed     Abstract available


  97. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    PubMed     Abstract available


  98. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    PubMed    


  99. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    PubMed    


  100. BRESSON-HADNI S, Montange D, Richou C, Brumpt E, et al
    Tobacco, cannabis, and liquorice: Hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis.
    J Hepatol. 2020 Dec 10. pii: S0168-8278(20)33749.
    PubMed    


  101. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    PubMed     Abstract available


  102. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    PubMed     Abstract available


  103. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    PubMed    


  104. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    PubMed    


  105. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    PubMed    


  106. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available


  107. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available


  108. MARTINEZ-CHANTAR ML, Foti M
    NFATc4: New hub in NASH development.
    J Hepatol. 2020;73:1313-1315.
    PubMed    


  109. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    PubMed    


  110. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    PubMed    


  111. MOSCA A, Panera N, Maggiore G, Alisi A, et al
    From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
    J Hepatol. 2020;73:1590-1592.
    PubMed    


  112. GOH BKP
    Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2020;73:1576.
    PubMed    


  113. HOBEIKA C, Fuks D
    Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.
    J Hepatol. 2020;73:1577-1578.
    PubMed    


  114. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    PubMed    


  115. MAK LY, Yuen MF, Seto WK
    Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    J Hepatol. 2020;73:1573-1574.
    PubMed    


  116. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    PubMed    


  117. ESLAM M, George J
    Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    J Hepatol. 2020;73:1575.
    PubMed    


  118. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    PubMed    


  119. JALAN R, Arroyo V
    Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
    J Hepatol. 2020;73:1316-1318.
    PubMed    


    November 2020
  120. KUPRIYANOVA Y, Zaharia OP, Bobrov P, Karusheva Y, et al
    Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
    J Hepatol. 2020 Nov 28. pii: S0168-8278(20)33817.
    PubMed     Abstract available


  121. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    PubMed     Abstract available


  122. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    PubMed     Abstract available


  123. DING Q, Ma Y, Lai S, Dou X, et al
    NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33812.
    PubMed    


  124. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    PubMed    


  125. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available


  126. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    PubMed     Abstract available


  127. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    PubMed     Abstract available


  128. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available


  129. GOLSE N, Joly F, Combari P, Lewin M, et al
    Predicting the risk of post-hepatectomy portal hypertension using a digital twin: a clinical proof of concept.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33761.
    PubMed     Abstract available


  130. ARECHEDERRA M, Bazai SK, Abdouni A, Sequera C, et al
    ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33758.
    PubMed     Abstract available


  131. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    PubMed     Abstract available


  132. KUCUKOGLU O, Sowa JP, Mazzolini GD, Syn WK, et al
    Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33746.
    PubMed     Abstract available


  133. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    PubMed    


  134. ANTOINE DJ, Jenkins RE, Dear JW, Williams DP, et al
    Retraction notice to "Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity": J Hepatol 56(2012)1070-1079.
    J Hepatol. 2020;73:1297.
    PubMed    


  135. JOTHIMANI D, Venugopal R, Abedin MF, Kaliamoorthy I, et al
    COVID-19 and the liver.
    J Hepatol. 2020;73:1231-1240.
    PubMed     Abstract available


  136. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    PubMed    


  137. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    PubMed    


  138. UNFRIED JP, Fortes P
    SMIM30, a tiny protein with a big role in liver cancer.
    J Hepatol. 2020;73:1010-1012.
    PubMed    


  139. HUANG J, Kumar R, Wang M, Zhu Y, et al
    MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    J Hepatol. 2020;73:1265-1267.
    PubMed    


  140. ESLAM M, George J
    Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    J Hepatol. 2020;73:1268-1269.
    PubMed    


  141. VAN HEES S, Muyindike W, Erem G, Ocama P, et al
    Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.
    J Hepatol. 2020;73:1271-1273.
    PubMed    


  142. SINGAL AG, Lampertico P, Nahon P
    Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda".
    J Hepatol. 2020;73:1273-1274.
    PubMed    


    October 2020
  143. WANG J, Wang Y, Chu Y, Li Z, et al
    Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.
    J Hepatol. 2020 Oct 30. pii: S0168-8278(20)33739.
    PubMed     Abstract available


  144. CHAN SL
    Hyperprogression in hepatocellular carcinoma: Illusion or reality?
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33669.
    PubMed    


  145. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available


  146. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    PubMed     Abstract available


  147. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    PubMed     Abstract available


  148. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    PubMed    


  149. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    PubMed    


  150. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    PubMed    


  151. ROSE CF, Amodio P, Bajaj JS, Dhiman RK, et al
    Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
    J Hepatol. 2020 Oct 21. pii: S0168-8278(20)30466.
    PubMed     Abstract available


  152. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    PubMed     Abstract available


  153. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available


  154. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    PubMed     Abstract available


  155. MORIKAWA R, Nakamoto N, Amiya T, Chu PS, et al
    Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33677.
    PubMed     Abstract available


  156. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    PubMed     Abstract available


  157. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    PubMed     Abstract available


  158. KIM TH, Koh YH, Kim BH, Kim MJ, et al
    Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33670.
    PubMed     Abstract available


  159. LIU C, Zha Z, Zhou C, Chen Y, et al
    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33674.
    PubMed     Abstract available


  160. FONDEVILA MF, Mercado-Gomez M, Rodriguez A, Gonzalez-Rellan MJ, et al
    Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33671.
    PubMed    


  161. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    PubMed    


  162. WANG Y, Lu F, Zhao J
    Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".
    J Hepatol. 2020;73:996-998.
    PubMed    


  163. MEHAL WZ
    From mice to humans: Unravelling the genetic levers of NASH.
    J Hepatol. 2020;73:749-751.
    PubMed    


  164. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    PubMed    


  165. HUO TI, Ho SY, Ko CC
    Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.
    J Hepatol. 2020;73:972-973.
    PubMed    


  166. SCHWARZKOPF KM, Eberle L, Uschner FE, Klein S, et al
    Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?
    J Hepatol. 2020;73:980-982.
    PubMed    


  167. TREBICKA J, Gu W, Garcia-Pagan JC, Bosch J, et al
    Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?
    J Hepatol. 2020;73:977-979.
    PubMed    


  168. XIANG X, Hwang S, Gao B
    Reply to: "Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?": The search for an optimal mouse model.
    J Hepatol. 2020;73:982-984.
    PubMed    


  169. ELHENCE A, Kumar R, Shalimar
    Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
    J Hepatol. 2020;73:976-977.
    PubMed    


  170. KIM N, Seong J
    Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".
    J Hepatol. 2020;73:973-974.
    PubMed    


    September 2020
  171. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    PubMed    


  172. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    PubMed    


  173. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    PubMed    


  174. SCHUMACHER N, Yan K, Gandrass M, Muller M, et al
    Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33664.
    PubMed     Abstract available


  175. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    PubMed    


  176. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    PubMed    


  177. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    PubMed    


  178. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Corrigendum to: "Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis" [J Hepatol (2020) 241-251].
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33603.
    PubMed    


  179. SECKLER F, Doussot A, Colpart P, Turco C, et al
    Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)30366.
    PubMed    


  180. SCHATTENBERG JM, Straub BK
    On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30475.
    PubMed    


  181. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    PubMed    


  182. KIM N, Cheng J, Jung I, Liang J, et al
    Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    J Hepatol. 2020 Sep 10. pii: S0168-8278(20)33602.
    PubMed    


  183. TONON M, Rosi S, Gambino CG, Piano S, et al
    Natural history of acute kidney disease in patients with cirrhosis.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33612.
    PubMed     Abstract available


  184. CHAN LK, Wai-Hung Ho D, Kam CS, Yung-Tuen Chiu E, et al
    RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33610.
    PubMed     Abstract available


  185. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
    J Hepatol. 2020 Sep 7. pii: S0168-8278(20)33591.
    PubMed    


  186. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    PubMed    


  187. MERLI M
    Nutrition in cirrhosis: Dos and Don'ts.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30474.
    PubMed    


  188. SERPER M, Shaked A, Olthoff KM, Hoteit M, et al
    A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.
    J Hepatol. 2020;73:708-709.
    PubMed    


  189. VALENTI L, Jamialahmadi O, Romeo S
    Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
    J Hepatol. 2020;73:709-711.
    PubMed    


  190. DI GIORGIO A, Nicastro E, Speziani C, De Giorgio M, et al
    Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.
    J Hepatol. 2020;73:702-705.
    PubMed    


  191. JI D, Xu J, Qin E, Zhang D, et al
    Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.
    J Hepatol. 2020;73:718-719.
    PubMed    


  192. BIQUARD L, Valla D, Rautou PE
    No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
    J Hepatol. 2020;73:717-718.
    PubMed    


  193. RICKE J, Sangro B, Malfertheiner P, Seidensticker M, et al
    Reply to: "Toxicity and dosimetry in SORAMIC study".
    J Hepatol. 2020;73:735-736.
    PubMed    


  194. REINDERS M, Braat A, Lam M
    Toxicity and dosimetry in SORAMIC study.
    J Hepatol. 2020;73:734-735.
    PubMed    


  195. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    PubMed    


  196. PAISANT A, Vilgrain V, Aube C
    Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    J Hepatol. 2020;73:716-717.
    PubMed    


  197. CHOI SH, Kim SY, Lim YS
    Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    J Hepatol. 2020;73:714-715.
    PubMed    


  198. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    PubMed    


  199. GUIU B
    Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.
    J Hepatol. 2020;73:727-728.
    PubMed    


  200. JI D, Zhang D, Lau G
    Reply to: 'NAFLD or comorbidities, that is the question'.
    J Hepatol. 2020;73:724-725.
    PubMed    


  201. PONZIANI FR, Gasbarrini A, Pompili M
    NAFLD or comorbidities, that is the question.
    J Hepatol. 2020;73:723.
    PubMed    


    August 2020
  202. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    PubMed    


  203. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    PubMed    


  204. CARACENI P, Tufoni M, Zaccherini G, Riggio O, et al
    On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)33551.
    PubMed     Abstract available


  205. XU Z, Li H, Tian S, Wu J, et al
    Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30371.
    PubMed    


  206. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30442.
    PubMed    


  207. FAN L, Lai R, Ma N, Dong Y, et al
    miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30541.
    PubMed     Abstract available


  208. RHEE H, Cho ES, Nahm JH, Jang M, et al
    Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30544.
    PubMed     Abstract available


  209. KIM CG, Kim C, Yoon SE, Kim KH, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Aug 15. pii: S0168-8278(20)30540.
    PubMed     Abstract available


  210. MANNING C, Alam SM
    Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30380.
    PubMed    


  211. SOLA E, Pose E, Campion D, Piano S, et al
    ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30536.
    PubMed     Abstract available


  212. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    PubMed     Abstract available


  213. IAVARONE M, D'Ambrosio R, Lampertico P
    Authors' reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19.
    J Hepatol. 2020 Aug 6. pii: S0168-8278(20)30524.
    PubMed    


  214. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    PubMed    


  215. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    PubMed     Abstract available


  216. JI D, Qin E, Xu J, Zhang D, et al
    Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
    J Hepatol. 2020;73:451-453.
    PubMed    


  217. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    PubMed    


  218. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    PubMed    


  219. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    PubMed    


    July 2020
  220. KOMOLL RM, Hu Q, Olarewaju O, von Dohlen L, et al
    MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    J Hepatol. 2020 Jul 30. pii: S0168-8278(20)30492.
    PubMed     Abstract available


  221. LUO YD, Fang L, Yu HQ, Zhang J, et al
    p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
    J Hepatol. 2020 Jul 29. pii: S0168-8278(20)30489.
    PubMed     Abstract available


  222. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available


  223. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    PubMed     Abstract available


  224. SANGRO B, Melero I, Wadhawan S, Finn RS, et al
    Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Jul 22. pii: S0168-8278(20)30479.
    PubMed     Abstract available


  225. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    PubMed     Abstract available


  226. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    PubMed     Abstract available


  227. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30388.
    PubMed    


  228. XU G, Xiao Y, Jin B, Sang X, et al
    Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30343.
    PubMed    


  229. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    PubMed     Abstract available


  230. SONG Y, An O, Ren X, Man Chan TH, et al
    RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.
    J Hepatol. 2020 Jul 18. pii: S0168-8278(20)30476.
    PubMed     Abstract available


  231. ZHANG X, Fan L, Wu J, Xu H, et al
    Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)".
    J Hepatol. 2020 Jul 17. pii: S0168-8278(20)30390.
    PubMed    


  232. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    PubMed    


  233. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez-Guerra M, et al
    Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30456.
    PubMed     Abstract available


  234. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    PubMed     Abstract available


  235. MCPHAIL MJW, Coen M
    Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30183.
    PubMed    


  236. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120).
    J Hepatol. 2020 Jul 10. pii: S0168-8278(20)30384.
    PubMed     Abstract available


  237. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
    J Hepatol. 2020 Jul 9. pii: S0168-8278(20)30389.
    PubMed    


  238. MOREAU R, Aguilar F, Arroyo V
    Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis".
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30340.
    PubMed    


  239. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    PubMed    


  240. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    PubMed    


  241. LAZARUS JV, Cortez-Pinto H, Anstee QM
    Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:221-222.
    PubMed    


  242. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    PubMed    


  243. LEUNG M, Piao C, Sarkar S
    NAFLD referral patterns in a large US academic center.
    J Hepatol. 2020;73:218-219.
    PubMed    


  244. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    PubMed    


  245. MENDEZ-SANCHEZ N, Valencia-Rodriguez A
    Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:220.
    PubMed    


  246. ZOU ZY, Fan JG
    Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:214-216.
    PubMed    


    June 2020
  247. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    PubMed     Abstract available


  248. DONG P, Wang X, Liu L, Tang W, et al
    Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    J Hepatol. 2020 Jun 28. pii: S0168-8278(20)30400.
    PubMed     Abstract available


  249. RUART M, Chavarria L, Camprecios G, Suarez-Herrera N, et al
    Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469].
    J Hepatol. 2020 Jun 27. pii: S0168-8278(20)30354.
    PubMed    


  250. LAMPL S, Janas MK, Donakonda S, Brugger M, et al
    Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30398.
    PubMed     Abstract available


  251. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    PubMed    


  252. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    PubMed    


  253. BASSEGODA O, Sola E, Gines P
    Reply to: "Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions".
    J Hepatol. 2020 Jun 21. pii: S0168-8278(20)30287.
    PubMed    


  254. GAO F, Huang ZM
    The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30397.
    PubMed    


  255. MEDHAT MA, El Kassas M
    Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19].
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30396.
    PubMed    


  256. KUMAR R, Kerbert AJC, Sheikh MF, Roth N, et al
    Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30381.
    PubMed     Abstract available


  257. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available


  258. COLNOT S, Lechel A
    Maternal obesity: A severe risk factor in hepatocarcinogenesis?
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30385.
    PubMed    


  259. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed     Abstract available


  260. SINGH I, De A, Singh V
    Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30184.
    PubMed    


  261. RAI RP, Liu Y, Iyer SS, Liu S, et al
    Blocking integrin alpha4beta7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30375.
    PubMed     Abstract available


  262. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    PubMed     Abstract available


  263. IAVARONE M, D'Ambrosio R, Soria A, Triolo M, et al
    High rates of 30-day mortality in patients with cirrhosis and COVID-19.
    J Hepatol. 2020 Jun 8. pii: S0168-8278(20)30365.
    PubMed     Abstract available


  264. JEPSEN P, Kraglund F, West J, Villadsen GE, et al
    Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
    J Hepatol. 2020 Jun 5. pii: S0168-8278(20)30363.
    PubMed     Abstract available


  265. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available


  266. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    PubMed    


  267. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    PubMed     Abstract available


  268. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    PubMed     Abstract available


  269. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    PubMed    


  270. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    PubMed    


  271. EDELINE J, Garin E
    Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90....
    J Hepatol. 2020;72:1046-1048.
    PubMed    


  272. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    PubMed    


  273. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    PubMed    


  274. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    PubMed    


  275. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    PubMed    


    May 2020
  276. DE SMET V, Verhulst S, van Grunsven LA
    Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2.
    J Hepatol. 2020 May 27. pii: S0168-8278(20)30349.
    PubMed    


  277. LUUKKONEN PK, Juuti A, Sammalkorpi H, Penttila AK, et al
    MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30234.
    PubMed    


  278. KIM N, Seong J
    Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
    J Hepatol. 2020 May 25. pii: S0168-8278(20)30229.
    PubMed    


  279. CHEW CA, Iyer SG, Chieh Kow AW, Madhavan K, et al
    An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.
    J Hepatol. 2020 May 23. pii: S0168-8278(20)30342.
    PubMed     Abstract available


  280. TELLEZ L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, et al
    Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30303.
    PubMed     Abstract available


  281. MOON AM, Webb GJ, Aloman C, Armstrong MJ, et al
    High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.
    J Hepatol. 2020 May 20. pii: S0168-8278(20)30305.
    PubMed    


  282. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    PubMed    


  283. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    PubMed    


  284. LUCIFORA J, Michelet M, Rivoire M, Protzer U, et al
    Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30204.
    PubMed    


  285. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    PubMed    


  286. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    PubMed    


  287. KUMAR A
    Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30175.
    PubMed    


  288. PENG ZP, Jiang ZZ, Guo HF, Zhou MM, et al
    Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30296.
    PubMed     Abstract available


  289. WANG Y, Liu S, Liu H, Li W, et al
    SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30294.
    PubMed     Abstract available


  290. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    PubMed    


  291. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    PubMed     Abstract available


  292. DESAI AP, Knapp SM, Orman ES, Ghabril MS, et al
    Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30289.
    PubMed     Abstract available


  293. MEYER T
    Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30232.
    PubMed    


  294. DAI Z, Ott M, Sharma AD
    Equal opportunity offer for all hepatocytes.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30200.
    PubMed    


  295. SCHWERBEL K, Kamitz A, Krahmer N, Hallahan N, et al
    Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30275.
    PubMed     Abstract available


  296. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    PubMed     Abstract available


  297. ABE H, Schuppan D
    beta-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.
    J Hepatol. 2020;72:813-815.
    PubMed    


    April 2020
  298. SERENARI M, Han KH, Ravaioli F, Kim SU, et al
    A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Apr 30. pii: S0168-8278(20)30276.
    PubMed     Abstract available


  299. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    PubMed     Abstract available


  300. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30214.
    PubMed    


  301. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


  302. FORREST E
    Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30117.
    PubMed    


  303. DEGRE D, Stauber RE, Deltenre P, Lackner C, et al
    Reply to: "Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30199.
    PubMed    


  304. OKINA Y, Sato-Matsubara M, Matsubara T, Daikoku A, et al
    TGF-beta-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.
    J Hepatol. 2020 Apr 17. pii: S0168-8278(20)30228.
    PubMed     Abstract available


  305. TAPPER EB, Asrani SK
    COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30217.
    PubMed     Abstract available


  306. TAPIAS EA, Ardevol A, Garcia-Guix M, Montanes R, et al
    Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30211.
    PubMed     Abstract available


  307. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213.
    PubMed     Abstract available


  308. LOPEZ-VICARIO C, Checa A, Urdangarin A, Aguilar F, et al
    Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30208.
    PubMed     Abstract available


  309. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    PubMed     Abstract available


  310. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30016.
    PubMed    


  311. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    PubMed    


  312. GANNE-CARRIE N, Piscaglia F
    Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?
    J Hepatol. 2020;72:607-609.
    PubMed    


  313. ENGELMANN C, Mehta G, Tacke F
    Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.
    J Hepatol. 2020;72:610-612.
    PubMed    


    March 2020
  314. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed     Abstract available


  315. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    PubMed     Abstract available


  316. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    PubMed     Abstract available


  317. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    PubMed     Abstract available


  318. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    PubMed     Abstract available


  319. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    PubMed     Abstract available


  320. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    PubMed    


  321. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.
    PubMed    


  322. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    PubMed    


  323. HASSAN M, Moghadamrad S, Sorribas M, Muntet SG, et al
    Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals.
    J Hepatol. 2020 Mar 20. pii: S0168-8278(20)30178.
    PubMed     Abstract available


  324. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    PubMed     Abstract available


  325. FRANCOZ C
    Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb.
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30113.
    PubMed    


  326. JIANG M, Deng H, Liu S, Su S, et al
    Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30067.
    PubMed    


  327. MOREAU R, Claria J, Aguilar F, Fenaille F, et al
    Correction to 'Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF' [J Hepatol 2020 (72) 688-701].
    J Hepatol. 2020 Mar 16. pii: S0168-8278(20)30131.
    PubMed    


  328. KIM N, Cheng J, Jung I, Liang J, et al
    Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30163.
    PubMed     Abstract available


  329. ALFAIATE D, Clement S, Gomes D, Goossens N, et al
    Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    J Hepatol. 2020 Mar 6. pii: S0168-8278(20)30129.
    PubMed     Abstract available


  330. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    PubMed     Abstract available


  331. GABR A, Ranganathan S, Mouli S, Riaz A, et al
    Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating the lung shunt study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30122.
    PubMed     Abstract available


  332. LIU Q, Yu J, Wang L, Tang Y, et al
    Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis.
    J Hepatol. 2020 Mar 2. pii: S0168-8278(20)30124.
    PubMed     Abstract available


  333. WONG VW
    Predicting NASH response with liver fat: Are we back to square one?
    J Hepatol. 2020;72:386-388.
    PubMed    


    February 2020
  334. BERARDI G, Troisi RI
    Reply to: "Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors".
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30069.
    PubMed    


  335. BANSAL R
    Battling IL-17, the troublemaker in alcohol-induced hepatocellular carcinoma.
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30109.
    PubMed    


  336. HUO TI, Liu PH, Hsu CY
    Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors.
    J Hepatol. 2020 Feb 28. pii: S0168-8278(20)30015.
    PubMed    


  337. ARFIANTI A, Pok S, Barn V, Haigh WG, et al
    Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30104.
    PubMed     Abstract available


  338. STADELMAYER B, Diederichs A, Chapus F, Rivoire M, et al
    Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30102.
    PubMed     Abstract available


  339. ARAB JP, Cabrera D, Sehrawat TS, Jalan-Sakrikar N, et al
    Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30103.
    PubMed     Abstract available


  340. HE F, Antonucci L, Yamachika S, Zhang Z, et al
    NRF2 Activates Growth Factor Genes and Downstream AKT Signaling to Induce Mouse and Human Hepatomegaly.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30070.
    PubMed     Abstract available


  341. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    PubMed     Abstract available


  342. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    PubMed     Abstract available


  343. KELLEY RK, Bridgewater J, Gores GJ, Zhu AX, et al
    Systemic therapies for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:353-363.
    PubMed     Abstract available


  344. SANGRO B, Chan SL, Meyer T, Reig M, et al
    Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    J Hepatol. 2020;72:320-341.
    PubMed     Abstract available


  345. CHENG AL, Hsu C, Chan SL, Choo SP, et al
    Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    J Hepatol. 2020;72:307-319.
    PubMed     Abstract available


  346. VIBERT E, Schwartz M, Olthoff KM
    Advances in resection and transplantation for hepatocellular carcinoma.
    J Hepatol. 2020;72:262-276.
    PubMed     Abstract available


  347. SINGAL AG, Lampertico P, Nahon P
    Epidemiology and surveillance for hepatocellular carcinoma: New trends.
    J Hepatol. 2020;72:250-261.
    PubMed     Abstract available


  348. REBOUISSOU S, Nault JC
    Advances in molecular classification and precision oncology in hepatocellular carcinoma.
    J Hepatol. 2020;72:215-229.
    PubMed     Abstract available


    January 2020
  349. TSENG TC, Liu CJ, Chang CT, Su TH, et al
    HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
    J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
    PubMed     Abstract available


  350. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    PubMed     Abstract available


  351. PAPATHEODORIDIS GV, Sypsa V, Dalekos GN, Yurdaydin C, et al
    Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30022.
    PubMed     Abstract available


  352. DEGRE D, Stauber RE, Englebert G, Sarocchi F, et al
    Long-term outcome of decompensated alcohol-related liver disease with steatohepatitis and Maddrey's discriminant function <32.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30014.
    PubMed     Abstract available


  353. NAMINENI S, O'Connor T, Faure-Dupuy S, Johansen P, et al
    A dual role for hepatocyte-intrinsic canonical NF-kappaB signaling in virus control.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30010.
    PubMed     Abstract available


  354. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    PubMed     Abstract available


  355. KOWALIK MA, Puliga E, Cabras L, Sulas P, et al
    Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30009.
    PubMed     Abstract available


  356. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    PubMed     Abstract available


  357. BUREAU C, Adebayo D, Chalret de Rieu M, Elkrief L, et al
    Corrigendum to 'Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study' [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2020 Jan 9. pii: S0168-8278(19)30723.
    PubMed    


  358. HAZARI Y, Bravo-San Pedro JM, Hetz C, Galluzzi L, et al
    Autophagy in hepatic adaptation to stress.
    J Hepatol. 2020;72:183-196.
    PubMed     Abstract available


    December 2019
  359. MA HY, Yamamoto G, Xu J, Liu X, et al
    IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
    J Hepatol. 2019 Dec 31. pii: S0168-8278(19)30761.
    PubMed     Abstract available


  360. DAI WQ, Xu L, Yu XN, Zhang GC, et al
    OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    J Hepatol. 2019 Dec 30. pii: S0168-8278(19)30760.
    PubMed     Abstract available


  361. DE VRIES E, Beuers U
    Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"
    J Hepatol. 2019 Dec 28. pii: S0168-8278(19)30705.
    PubMed    


  362. DONG LQ, Peng LH, Ma LJ, Liu DB, et al
    Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30759.
    PubMed     Abstract available


  363. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available


  364. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    PubMed     Abstract available


  365. KUMAR P, Kulkarni A
    UDCA therapy in intrahepatic cholestasis of pregnancy?
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30653.
    PubMed    


  366. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30718.
    PubMed     Abstract available


  367. ZHANG Z, Xu X, Tian W, Jiang R, et al
    ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.
    J Hepatol. 2019 Dec 16. pii: S0168-8278(19)30716.
    PubMed     Abstract available


  368. CHEUK-FUNG YIP T, Lai-Hung Wong G, Wai-Sun Wong V, Tse YK, et al
    Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    J Hepatol. 2019 Dec 16. pii: S0168-8278(19)30717.
    PubMed     Abstract available


  369. DHAWAN A, Chaijitraruch N, Fitzpatrick E, Bansal S, et al
    Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children.
    J Hepatol. 2019 Dec 13. pii: S0168-8278(19)30714.
    PubMed     Abstract available


  370. PEI T, Meng F, Xiao P, Han J, et al
    MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    J Hepatol. 2019 Dec 11. pii: S0168-8278(19)30713.
    PubMed     Abstract available


  371. PARK HJ, Jang HY, Kim SY, Lee SJ, et al
    Non-enhanced Magnetic Resonance Imaging as a Surveillance Tool for Hepatocellular Carcinoma: Comparison with Ultrasound.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30712.
    PubMed     Abstract available


  372. SOLE C, Sola E, Kamath PS, Gines P, et al
    Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30554.
    PubMed    


  373. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    PubMed     Abstract available


  374. GARCIA-TSAO G, Angeli P, Nadim MK, Parikh CR, et al
    Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis".
    J Hepatol. 2019 Dec 3. pii: S0168-8278(19)30673.
    PubMed    


  375. JALAN R, Bataller R, Berg T, Lotersztajn S, et al
    Journal of Hepatology: The Home of Liver Research, 2015-2019.
    J Hepatol. 2019;71:1065-1069.
    PubMed    


    November 2019
  376. CUCCHETTI A, Zhong J, Berhane S, Toyoda H, et al
    The chances of hepatic resection curing hepatocellular carcinoma.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30703.
    PubMed     Abstract available


  377. BONNIN M, Fares N, Testoni B, Estornes Y, et al
    Corrigendum to "Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis" [J Hepatol 71 (2019) 763-772].
    J Hepatol. 2019 Nov 25. pii: S0168-8278(19)30651.
    PubMed    


  378. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    PubMed     Abstract available


  379. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
    A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
    PubMed     Abstract available


  380. FERENCI P
    Are all cirrhotic patients equal?
    J Hepatol. 2019 Nov 6. pii: S0168-8278(19)30649.
    PubMed    


  381. HARRISON SA, Alkhouri N, Davison BA, Sanyal A, et al
    Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650.
    PubMed     Abstract available


  382. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    PubMed     Abstract available


    October 2019
  383. BERNAL W, Caldwell SH, Lisman T
    Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis?
    J Hepatol. 2019 Oct 29. pii: S0168-8278(19)30590.
    PubMed    


  384. YAU T, Hsu C, Kim TY, Choo SP, et al
    Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
    J Hepatol. 2019 Oct 24. pii: S0168-8278(19)30551.
    PubMed    


  385. SHEN YC, Hsu CL, Jeng YM, Ho MC, et al
    Reliability of a Single-region Sample to evaluate Immune Tumor Microenvironment in Hepatocellular Carcinoma.
    J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30608.
    PubMed     Abstract available


  386. SIDDIQUI MS, Van Natta ML, Connelly MA, Vuppalanchi R, et al
    Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis.
    J Hepatol. 2019 Oct 18. pii: S0168-8278(19)30607.
    PubMed     Abstract available


  387. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    PubMed     Abstract available


  388. LI Y, Tang L, Guo L, Chen C, et al
    CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
    PubMed     Abstract available


  389. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    PubMed     Abstract available


    September 2019
  390. JIANG F, Chen Q, Wang W, Ling Y, et al
    Hepatocyte-Derived Extracellular Vesicles Promote Endothelial Inflammation and Atherogenesis via microRNA-1.
    J Hepatol. 2019 Sep 27. pii: S0168-8278(19)30552.
    PubMed     Abstract available


  391. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30527.
    PubMed    


  392. MARTIN MATEOS R, Maddur H
    A step forward to accurately predict mortality in cirrhotic patients undergoing elective surgery: The role of the hepatic venous pressure gradient.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30529.
    PubMed    


  393. KHAN SA, Genus T, Morement H, Murphy A, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30466.
    PubMed    


  394. GASPERSZ MP, Klompenhouwer AJ, Broker MEE, Thomeer MGJ, et al
    Growth of hepatocellular adenoma during pregnancy: a prospective study.
    J Hepatol. 2019 Sep 21. pii: S0168-8278(19)30548.
    PubMed     Abstract available


  395. TOH TB, Lim JJ, Hooi L, Rashid MBMA, et al
    Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/beta-catenin-driven hepatocellular carcinoma.
    J Hepatol. 2019 Sep 18. pii: S0168-8278(19)30547.
    PubMed     Abstract available


  396. VITALE A, Majno-Hurst P
    Towards a personalized approach to hepatic resection in cirrhotic patients.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30541.
    PubMed    


  397. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed     Abstract available


  398. RASSI AB, d'Amico EA, Tripodi A, Rocha TRFD, et al
    Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30544.
    PubMed     Abstract available


  399. TSCHUOR C, Kummerli C, Dutkowski P, Hernandez-Alejandro R, et al
    Reply to: "Canadian liver transplant allocation for hepatocellular carcinoma".
    J Hepatol. 2019 Sep 7. pii: S0168-8278(19)30463.
    PubMed    


  400. MCLIN VA, Braissant O, Cudalbu C
    Reply to: "Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?"
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30469.
    PubMed    


  401. HERMANN B, Rudler M, Galanaud D, Thabut D, et al
    Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30416.
    PubMed    


  402. BERARDI G, Morise Z, Sposito C, Igarashi K, et al
    Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in child-pugh b cirrhosis.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30526.
    PubMed     Abstract available


  403. WEI Y, Shi D, Liang Z, Liu Y, et al
    IL-17A Secreted from Lymphatic Endothelial Cells Promotes Tumorigenesis by Up-regulation of PD-L1 in Hepatoma Stem Cells.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30528.
    PubMed     Abstract available


  404. BRAHMANIA M, Marquez V, Kneteman NM, Bhat M, et al
    Canadian liver transplant allocation for hepatocellular carcinoma.
    J Hepatol. 2019 Sep 5. pii: S0168-8278(19)30425.
    PubMed    


    August 2019
  405. TOVOLI F, Ielasi L, Casadei-Gardini A, Granito A, et al
    Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
    J Hepatol. 2019 Aug 23. pii: S0168-8278(19)30482.
    PubMed     Abstract available


  406. HOU J, Zhang H, Sun B, Karin M, et al
    The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications.
    J Hepatol. 2019 Aug 23. pii: S0168-8278(19)30481.
    PubMed     Abstract available


  407. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    PubMed     Abstract available


  408. RICKE J, Klumpen HJ, Amthauer H, Bargellini I, et al
    Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472.
    PubMed     Abstract available


  409. MOURIES J, Brescia P, Silvestri A, Spadoni I, et al
    Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    J Hepatol. 2019 Aug 13. pii: S0168-8278(19)30471.
    PubMed     Abstract available


  410. KIM BK
    Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
    J Hepatol. 2019 Aug 2. pii: S0168-8278(19)30412.
    PubMed    


  411. HAKIM A, Mistry PK, Vilarinho S
    Reply to: "Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges".
    J Hepatol. 2019 Aug 1. pii: S0168-8278(19)30413.
    PubMed    


    July 2019
  412. VALENTI L, Pelusi S, Baselli G
    Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges.
    J Hepatol. 2019 Jul 27. pii: S0168-8278(19)30355.
    PubMed    


  413. MORAIS R, Liberal R, Santos A, Pita I, et al
    Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis.
    J Hepatol. 2019 Jul 27. pii: S0168-8278(19)30357.
    PubMed    


  414. CHOI J, Lim YS
    Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30385.
    PubMed    


  415. HERNANDEZ-TEJERO M, Triolo M, Fernandez J
    Reply to: "Another clinical unmet need in liver patients: Multidrug-resistant bacteria in decompensated cirrhosis".
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30403.
    PubMed    


  416. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Genomic Sequencing Identifies WNK2 as a Driver in hepatocellular carcinoma and a Risk Factor for Early Recurrence.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30423.
    PubMed     Abstract available


  417. FAURE-DUPUY S, Delphin M, Aillot L, Dimier L, et al
    Hepatitis B Virus-induced modulation of liver macrophage function promotes hepatocyte infection.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30422.
    PubMed     Abstract available


  418. REVERTER E, Cirera I, Albillos A, Debernardi-Venon W, et al
    The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery.
    J Hepatol. 2019 Jul 19. pii: S0168-8278(19)30415.
    PubMed     Abstract available


  419. LOGLIO A, Ferenci P, Colonia Uceda Renteria S, Tham CYL, et al
    Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30411.
    PubMed     Abstract available


  420. ANGELI P, Garcia-Tsao G, Nadim MK, Parikh CR, et al
    News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: a step beyond the International Club of Ascites (ICA) Consensus document.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30410.
    PubMed     Abstract available


  421. MUN SJ, Ryu JS, Lee MO, Son YS, et al
    Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.
    J Hepatol. 2019 Jul 9. pii: S0168-8278(19)30402.
    PubMed     Abstract available


  422. SORRIBAS M, Jakob MO, Yilmaz B, Li H, et al
    FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30389.
    PubMed     Abstract available


  423. GORG B, Karababa A, Schutz E, Paluschinski M, et al
    O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30392.
    PubMed     Abstract available


    June 2019
  424. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    PubMed     Abstract available


  425. MAJUMDAR A, Roberts SK, Pilcher D
    Are liver transplant centres critical for the critically ill patient with cirrhosis?
    J Hepatol. 2019 Jun 21. pii: S0168-8278(19)30288.
    PubMed    


  426. DURAND F, Pavesi M, Cheung R
    Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?
    J Hepatol. 2019 Jun 19. pii: S0168-8278(19)30304.
    PubMed    


  427. RYAN MC, Zelber-Sagi S
    Hepatic fat: Pathogenic trigger or passenger?
    J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30302.
    PubMed    


  428. BORST K, Graalmann T, Kalinke U
    Reply to: "Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers".
    J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30298.
    PubMed    


  429. BONNIN M, Fares N, Testoni B, Estornes Y, et al
    KfouryToll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
    J Hepatol. 2019 Jun 17. pii: S0168-8278(19)30351.
    PubMed     Abstract available


  430. LEFERE S, Degroote H, Van Vlierberghe H, Devisscher L, et al
    Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers.
    J Hepatol. 2019 Jun 15. pii: S0168-8278(19)30187.
    PubMed    


  431. O'ROURKE JM, Patten DA, Shetty S
    Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses.
    J Hepatol. 2019 Jun 14. pii: S0168-8278(19)30305.
    PubMed    


  432. PRODEAU M, Drumez E, Duhamel A, Vibert E, et al
    An Ordinal Model to Predict the Risk of Symptomatic Liver Failure in Patients with Cirrhosis undergoing Hepatectomy.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30346.
    PubMed     Abstract available


  433. LIU Y, Lu T, Zhang C, Xu J, et al
    Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-Reperfusion Injury.
    J Hepatol. 2019 Jun 12. pii: S0168-8278(19)30344.
    PubMed     Abstract available


  434. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    PubMed     Abstract available


  435. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    PubMed    


  436. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    PubMed     Abstract available


  437. WANG X, He Q, Shen H, Xia A, et al
    TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30301.
    PubMed     Abstract available


  438. BRAISSANT O, Rackayova V, Pierzchala K, Grosse J, et al
    Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30308.
    PubMed     Abstract available


  439. YANG S, Wang L, Pan W, Bayer W, et al
    MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30299.
    PubMed     Abstract available


  440. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    PubMed     Abstract available


    May 2019
  441. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    PubMed     Abstract available


  442. IOANNOU GN, Green P, Kerr KF, Berry K, et al
    Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    J Hepatol. 2019 May 27. pii: S0168-8278(19)30291.
    PubMed     Abstract available


  443. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    PubMed    


  444. JOUVE JL, Lecomte T, Bouche O, Barbier E, et al
    Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.
    J Hepatol. 2019 May 21. pii: S0168-8278(19)30289.
    PubMed     Abstract available


  445. KIM DH, Choi SH, Byun JH, Kang JH, et al
    Arterial Subtraction Images of Gadoxetate-Enhanced MRI Improve Diagnosis of Early-Stage Hepatocellular Carcinoma.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30286.
    PubMed     Abstract available


  446. FONTANELLAS A, Avila MA, Anderson KE, Deybach JC, et al
    Current and innovative emerging therapies for porphyrias with hepatic involvement.
    J Hepatol. 2019 May 15. pii: S0168-8278(19)30282.
    PubMed     Abstract available


  447. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Abstract available


  448. GEPNER Y, Shelef I, Komy O, Cohen N, et al
    The Beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.
    J Hepatol. 2019 May 7. pii: S0168-8278(19)30274.
    PubMed     Abstract available


  449. NISHIO T, Hu R, Koyama Y, Liang S, et al
    Activated Hepatic Stellate Cells and Portal Fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30273.
    PubMed     Abstract available


  450. HALDAR D, Kern B, Hodson J, James Armstrong M, et al
    Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30272.
    PubMed     Abstract available


  451. CHEN DP, Ning WR, Jiang ZZ, Peng ZP, et al
    Glycolytic Activation of Peritumoral Monocytes Fosters Immune Privilege via PFKFB3-PD-L1 axis in Human Hepatocellular Carcinoma.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30268.
    PubMed     Abstract available


  452. GALLINA P, Gallo O, Nicoletti C, Romanelli RG, et al
    A hydrodynamic hypothesis for the pathogenesis of glymphatic system impairment in hepatic encephalopathy.
    J Hepatol. 2019 May 3. pii: S0168-8278(19)30124.
    PubMed    


    April 2019
  453. OTT M, Castell JV
    Hepatocyte transplantation, a step forward?
    J Hepatol. 2019 Apr 17. pii: S0168-8278(19)30193.
    PubMed    


  454. ALEKSIEVA N, Forbes SJ
    Biliary-derived hepatocytes in chronic liver injury: Bringing new troops to the battlefield?
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30185.
    PubMed    


  455. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    PubMed     Abstract available


  456. OVEREEM AW, Klappe K, Parisi S, Kloters-Planchy P, et al
    Pluripotent stem cell-derived bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30225.
    PubMed     Abstract available


  457. WANDELER G, Mauron E, Atkinson A, Dufour JF, et al
    Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30226.
    PubMed     Abstract available


  458. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Abstract available


  459. GERARD C, Di-Luoffo M, Gonay L, Caruso S, et al
    Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
    J Hepatol. 2019 Apr 3. pii: S0168-8278(19)30195.
    PubMed     Abstract available


    March 2019
  460. ARONSON SJ, Bakker RS, Shi X, Duijst S, et al
    Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice.
    J Hepatol. 2019 Mar 29. pii: S0168-8278(19)30192.
    PubMed     Abstract available


  461. JEONG KANG H, Oh JH, Chun SM, Kim D, et al
    Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
    J Hepatol. 2019 Mar 28. pii: S0168-8278(19)30189.
    PubMed     Abstract available


  462. ZHANG X, Fan L, Wu J, Xu H, et al
    Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization.
    J Hepatol. 2019 Mar 23. pii: S0168-8278(19)30184.
    PubMed     Abstract available


  463. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Mar 22. pii: S0168-8278(19)30183.
    PubMed     Abstract available


  464. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    PubMed     Abstract available


  465. BAYO J, Fiore EJ, Dominguez LM, Real A, et al
    A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30148.
    PubMed     Abstract available


  466. XU X, Zhang HL, Liu QP, Sun SW, et al
    Radiomic Analysis of Contrast-Enhanced CT Predicts Microvascular Invasion and Outcome in Hepatocellular Carcinoma.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30145.
    PubMed     Abstract available


  467. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    PubMed     Abstract available


  468. MEYER T, Johnson P
    Trial endpoints for systemic therapy in patients with hepatocellular carcinoma.
    J Hepatol. 2019 Mar 11. pii: S0168-8278(19)30137.
    PubMed    


  469. FRANCOZ C, Sola E
    Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.
    J Hepatol. 2019 Mar 1. pii: S0168-8278(19)30118.
    PubMed    


  470. YAN WT, Quan B, Xing H, Wu MC, et al
    Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection.
    J Hepatol. 2019;70:570-571.
    PubMed    


    February 2019
  471. HERNANDEZ-GEA V, Gottardi A, Leebeek FWG, Rautou PE, et al
    Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis.
    J Hepatol. 2019 Feb 26. pii: S0168-8278(19)30130.
    PubMed     Abstract available


  472. MANCO R, Clerbaux LA, Verhulst S, Nader MB, et al
    Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30117.
    PubMed     Abstract available


  473. DEVARBHAVI H, Asrani SK, Kamath PS
    Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30066.
    PubMed    


  474. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    PubMed    


  475. HOUGHTON D, Zalewski P, Hallsworth K, Cassidy S, et al
    The degree of hepatic steatosis associates with impaired cardiac and autonomic function.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30112.
    PubMed     Abstract available


  476. TAPPER EB, Romero-Gomez M, Bajaj JS
    Hepatic encephalopathy and traffic accidents: Vigilance is needed!
    J Hepatol. 2019 Feb 11. pii: S0168-8278(19)30031.
    PubMed    



  477. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].
    J Hepatol. 2019 Feb 7. pii: S0168-8278(19)30034.
    PubMed    


  478. MORTON A
    Splenic artery aneurysms, portal hypertension and pregnancy.
    J Hepatol. 2019 Feb 4. pii: S0168-8278(18)32638.
    PubMed    


  479. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy".
    J Hepatol. 2019 Feb 4. pii: S0168-8278(19)30017.
    PubMed    


  480. GANNE-CARRIE N, Nahon P
    Hepatocellular carcinoma in the setting of alcohol-related liver disease.
    J Hepatol. 2019;70:284-293.
    PubMed     Abstract available


  481. GAO B, Ahmad MF, Nagy LE, Tsukamoto H, et al
    Inflammatory pathways in alcoholic steatohepatitis.
    J Hepatol. 2019;70:249-259.
    PubMed     Abstract available


  482. BELDI G, Vuitton D, Lachenmayer A, Heyd B, et al
    Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?
    J Hepatol. 2019 Feb 1. pii: S0168-8278(18)32630.
    PubMed    


    January 2019
  483. BORST K, Graalmann T, Kalinke U
    Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".
    J Hepatol. 2019 Jan 31. pii: S0168-8278(19)30013.
    PubMed    


  484. SOLA E, Sole C, Gines P
    Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out...".
    J Hepatol. 2019 Jan 30. pii: S0168-8278(18)32646.
    PubMed    


  485. SANZ-GARCIA C, Poulsen KL, Bellos D, Wang H, et al
    The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.
    J Hepatol. 2019 Jan 30. pii: S0168-8278(19)30064.
    PubMed     Abstract available


  486. KESSLER SM, Hoppstadter J, Hosseini K, Laggai S, et al
    Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.
    J Hepatol. 2019 Jan 24. pii: S0168-8278(18)32569.
    PubMed    


  487. FERRARESE A, Feltracco P, Barbieri S, Cillo U, et al
    Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32389.
    PubMed    


  488. VAN DER MERWE S, Laleman W, Langouche L, Meersseman P, et al
    Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30007.
    PubMed    


  489. SINGH V, Singh A, Agarwal R
    Midodrine and albumin in decompensated cirrhosis: Down but not out....
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32540.
    PubMed    


  490. XIANG X, Wang Y, Mo DC, Wang SQ, et al
    Liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection: A comment for moving forward.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32572.
    PubMed    


  491. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Abstract available


  492. WEI W, Li L, Kong G, Zheng Z, et al
    Spleen in hepatocellular carcinoma: More complexity and importance than we knew.
    J Hepatol. 2019 Jan 22. pii: S0168-8278(18)32573.
    PubMed    


  493. GRANCINI V, Trombetta M, Lunati ME, Boselli ML, et al
    Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30028.
    PubMed     Abstract available


  494. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30029.
    PubMed     Abstract available


  495. PAUMELLE R, Haas J, Hennuyer N, Bauge E, et al
    Hepatic PPARalpha is critical in the metabolic adaptation to sepsis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30027.
    PubMed     Abstract available


  496. HUO TI, Liu PH, Hsu CY
    Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(18)32571.
    PubMed    


  497. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection".
    J Hepatol. 2019 Jan 17. pii: S0168-8278(18)32645.
    PubMed    


  498. WANG Q, Xia D, Bai W, Wang E, et al
    Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.
    J Hepatol. 2019 Jan 17. pii: S0168-8278(19)30025.
    PubMed     Abstract available


  499. BARAHMAN M, Zhang W, Yaffe Harris H, Aiyer A, et al
    Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30022.
    PubMed     Abstract available


  500. XU QG, Yuan SX, Tao QF, Yu J, et al
    A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30018.
    PubMed     Abstract available


  501. VAN WETTERE M, Purcell Y, Bruno O, Payance A, et al
    Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30021.
    PubMed     Abstract available


  502. HSU YC, Yip TC, Ho HJ, Wong VW, et al
    Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629.
    PubMed    


  503. HSU YC, Yip TC, Wong GL, Wu CY, et al
    Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32583.
    PubMed    


  504. FORMENTIN C, De Rui M, Zoncape M, Ceccato S, et al
    The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability.
    J Hepatol. 2019 Jan 8. pii: S0168-8278(19)30005.
    PubMed     Abstract available


  505. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    PubMed     Abstract available


  506. YOO JJ, Kim SG, Kim YS, Lee B, et al
    Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30004.
    PubMed     Abstract available


  507. GOLDARACENA N, Gorgen A, Doyle A, Hansen BE, et al
    Live Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Offers Increased Survival vs. Deceased Donation.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30003.
    PubMed     Abstract available


  508. TISCHENDORF M, Fuchs A, Zeuzem S, Lange CM, et al
    Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32570.
    PubMed    


  509. TSAI JF, Perng DS
    Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32546.
    PubMed    


  510. ZHANG Y, Pei Y, Chen X, Zhang W, et al
    Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32524.
    PubMed    


  511. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32631.
    PubMed    


  512. QIN JJ, Mao W, Wang X, Sun P, et al
    Corrigendum to "Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1" [J Hepatol 69 (2018) 1110-1122].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32522.
    PubMed    


  513. DOYLE A, Gorgen A, Muaddi H, Aravinthan AD, et al
    Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients.
    J Hepatol. 2019 Jan 4. pii: S0168-8278(19)30001.
    PubMed     Abstract available


  514. NOBILI V, Schwimmer JB, Vajro P
    Breastfeeding and NAFLD from the maternal side of the mother-infant dyad.
    J Hepatol. 2019;70:13-14.
    PubMed    


  515. DIAZ A, Forner A
    Prognosis assessment by pathologist: Is the detection of intratumoural tertiary lymphoid structures a reliable tool?
    J Hepatol. 2019;70:11-12.
    PubMed    


    December 2018
  516. MOHKAM K, Mabrut JY
    Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?"
    J Hepatol. 2018 Dec 24. pii: S0168-8278(18)32579.
    PubMed    


  517. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32635.
    PubMed     Abstract available


  518. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Abstract available


  519. ZHANG YM, Zhou ZT, Liu GM
    Factors predicting early recurrence after surgical resection of hepatocellular carcinoma.
    J Hepatol. 2018 Dec 19. pii: S0168-8278(18)32523.
    PubMed    


  520. CHAN AWH, Berhane S, Cucchetti A, Johnson PJ, et al
    Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection".
    J Hepatol. 2018 Dec 18. pii: S0168-8278(18)32577.
    PubMed    


  521. DE OLIVEIRA S, Houseright RA, Graves AL, Golenberg N, et al
    Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    J Hepatol. 2018 Dec 17. pii: S0168-8278(18)32622.
    PubMed     Abstract available


  522. KUSAKABE J, Firl DJ, Sasaki K
    Toward the universal scoring system in treatment for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32508.
    PubMed    


  523. ZHANG XY, Ou J, Chen JY, Li WW, et al
    Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32491.
    PubMed    


  524. RINELLA ME, Trotter JF, Abdelmalek MF, Paredes AH, et al
    Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis.
    J Hepatol. 2018 Dec 7. pii: S0168-8278(18)32615.
    PubMed     Abstract available


  525. PARK JW, Kim YJ, Kim DY, Bae SH, et al
    Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial.
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32580.
    PubMed     Abstract available


  526. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed    


  527. ICHAI P, Laurent-Bellue A, Camus C, Moreau D, et al
    Liver transplantation in patients with liver failure related to exertional heatstroke.
    J Hepatol. 2018 Dec 3. pii: S0168-8278(18)32575.
    PubMed     Abstract available


    November 2018
  528. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed    



  529. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed    


  530. OTETE H, Deleuran T, Fleming KM, Card T, et al
    Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?"
    J Hepatol. 2018 Nov 10. pii: S0168-8278(18)32459.
    PubMed    


  531. YU SJ, Ma C, Heinrich B, Brown ZJ, et al
    Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32525.
    PubMed     Abstract available


  532. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    PubMed     Abstract available


  533. WEISS N, Housset C, Thabut D
    Hepatic encephalopathy: Another brick in the wall.
    J Hepatol. 2018 Nov 7. pii: S0168-8278(18)32499.
    PubMed    


  534. ROY A, Taneja S
    Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse.
    J Hepatol. 2018 Nov 3. pii: S0168-8278(18)32384.
    PubMed    


  535. THULUVATH PJ, Thuluvath AJ, Hanish S, Savva Y, et al
    Reply to: "Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse".
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32496.
    PubMed    


  536. FERNANDEZ J, Prado V, Trebicka J, Amoros A, et al
    Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
    J Hepatol. 2018 Nov 1. pii: S0168-8278(18)32511.
    PubMed     Abstract available


    October 2018
  537. RAVEN A, Forbes SJ
    Hepatic progenitors in liver regeneration.
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)30154.
    PubMed    


  538. ZHAO LY, Luo YJ, Zhu J, Liu HY, et al
    Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)32386.
    PubMed    


  539. METWALLY M, Bayoumi A, Romero-Gomez M, Thabet K, et al
    A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32505.
    PubMed     Abstract available


  540. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32506.
    PubMed     Abstract available


  541. KIM HY, So YH, Kim W, Ahn DW, et al
    Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32502.
    PubMed     Abstract available


  542. YIP TC, Wong GL, Chan HL, Tse YK, et al
    HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32497.
    PubMed     Abstract available


  543. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed    


  544. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed    


  545. D'AMICO G, Bataller R
    Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Oct 11. pii: S0168-8278(18)32447.
    PubMed    


  546. O'BRIEN A, Kamath PS, Trotter J
    MACHT - Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list.
    J Hepatol. 2018 Oct 9. pii: S0168-8278(18)32444.
    PubMed    


  547. JAYAKUMAR S, Middleton MS, Lawitz EJ, Mantry PS, et al
    Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib.
    J Hepatol. 2018 Oct 3. pii: S0168-8278(18)32443.
    PubMed     Abstract available


  548. GIANNINI EG, Bodini G, Furnari M, Marabotto E, et al
    NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.
    J Hepatol. 2018;69:972-973.
    PubMed    


  549. DE FRANCHIS R, Krag A
    Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
    J Hepatol. 2018;69:769-771.
    PubMed    


  550. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32441.
    PubMed     Abstract available


  551. SAGGI H, Maitra D, Jiang A, Zhang R, et al
    Loss of hepatocyte beta-Catenin protects mice from experimental porphyria-associated liver injury.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442.
    PubMed     Abstract available


    September 2018
  552. DEUGNIER Y, Morcet J, Laine F, Hamdi-Roze H, et al
    Reduced phenotypic expression in genetic hemochromatosis with time: role of exposure to nongenetic modifiers.
    J Hepatol. 2018 Sep 20. pii: S0168-8278(18)32383.
    PubMed     Abstract available


  553. LOW JTS, Rohde G, Pittordou K, Candy B, et al
    Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals.
    J Hepatol. 2018 Sep 19. pii: S0168-8278(18)32381.
    PubMed     Abstract available


  554. KIM Y, Kang K, Lee SB, Seo D, et al
    Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32380.
    PubMed     Abstract available


  555. FERNANDEZ J, Saliba F
    Liver transplantation in patients with ACLF and multiple organ failure: Time for priority after initial stabilization.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32372.
    PubMed    


  556. CHAN AWH, Zhong J, Berhane S, Toyoda H, et al
    Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.
    J Hepatol. 2018 Sep 17. pii: S0168-8278(18)32378.
    PubMed     Abstract available


  557. ZHANG T, Hu J, Wang X, Zhao X, et al
    MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NFkappaB-TNFalpha Pathway.
    J Hepatol. 2018 Sep 12. pii: S0168-8278(18)32376.
    PubMed     Abstract available


  558. CALDERARO J, Petitprez F, Becht E, Laurent A, et al
    Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32373.
    PubMed     Abstract available


  559. TORGERSON PR, Schweiger A, Deplazes P, Pohar M, et al
    Corrigendum to "Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35years" [J Hepatol 49 (2008) 72-77].
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32292.
    PubMed    


  560. SHEARER J, Chizhande D, Jones R, Rowe IA, et al
    Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32282.
    PubMed    


  561. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Impaired brain glymphatic flow in experimental hepatic encephalopathy.
    J Hepatol. 2018 Sep 7. pii: S0168-8278(18)32367.
    PubMed     Abstract available


  562. GUSTOT T, Moreau R
    Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis.
    J Hepatol. 2018 Sep 6. pii: S0168-8278(18)32370.
    PubMed     Abstract available


  563. PETTA S, Sebastiani G, de Ledinghen V
    Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32300.
    PubMed    


  564. GJORGJIEVA M, Calderaro J, Monteillet L, Silva M, et al
    Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32271.
    PubMed     Abstract available


  565. RODRIGUES PM, Perugorria MJ, Santos-Laso A, Bujanda L, et al
    Primary biliary cholangitis: a tale of epigenetically-induced secretory failure?
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32362.
    PubMed     Abstract available


  566. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    PubMed    


    August 2018

  567. Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32290.
    PubMed    


  568. YOUNOSSI Z, Stepanova M, Sanyal AJ, Harrison SA, et al
    The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295.
    PubMed     Abstract available


  569. CUBERO FJ, Peng J, Liao L, Su H, et al
    Inactivation of Caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32297.
    PubMed     Abstract available


  570. MOREAU R, Bataller R, Berg T, Lotersztajn S, et al
    Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268].
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32281.
    PubMed    


  571. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32286.
    PubMed     Abstract available


  572. CLARK VC, Marek G, Liu C, Collinsworth A, et al
    Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32284.
    PubMed     Abstract available


  573. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Abstract available


  574. SOLA E, Sole C, Simon-Talero M, Martin-Llahi M, et al
    MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32285.
    PubMed     Abstract available


  575. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Abstract available


  576. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32269.
    PubMed    


  577. ASRANI SK, Saracino G, O'Leary JG, Gonzalez S, et al
    Corrigendum to "Recipient characteristics and morbidity and mortality after liver transplantation" [J hepatol 69 (2018) 43-50].
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32268.
    PubMed    


  578. YANG X, Chen J, Wang N, Liu Z, et al
    Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: How far we are?
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32183.
    PubMed    


  579. GANNE-CARRIE N, Chaffaut C, Bourcier V, Archambeaud I, et al
    Estimate of hepatocellular carcinoma's incidence in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32278.
    PubMed     Abstract available


  580. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].
    J Hepatol. 2018 Aug 3. pii: S0168-8278(18)32263.
    PubMed    


    July 2018
  581. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    PubMed     Abstract available


  582. MAROT A, Henrion J, Knebel JF, Deltenre P, et al
    Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32160.
    PubMed    


  583. LAUTERIO A, Moioli MC, Di Sandro S, Travi G, et al
    HIV-positive to HIV-positive liver transplantation: To be continued.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32180.
    PubMed    


  584. AJI T, Dong JH, Shao YM, Zhao JM, et al
    Ex vivo Liver Resection and Autotransplantation as Alternative to Allotransplantation for End-stage Hepatic Alveolar Echinococcosis.
    J Hepatol. 2018 Jul 19. pii: S0168-8278(18)32258.
    PubMed     Abstract available


  585. SCOTT CL, Guilliams M
    The role of Kupffer cells in hepatic iron and lipid metabolism.
    J Hepatol. 2018 Jul 9. pii: S0168-8278(18)30130.
    PubMed    


  586. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    PubMed    


  587. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Abstract available


  588. LAI SW, Lin CL, Liao KF
    Association between cirrhosis and hip fracture in older people in a population-based cohort study.
    J Hepatol. 2018 Jul 2. pii: S0168-8278(18)32060.
    PubMed    


    June 2018
  589. HUTCHINSON JA, Schlitt HJ
    Subclinical T cell-mediated liver transplant rejection: The jury is still out.
    J Hepatol. 2018 Jun 30. pii: S0168-8278(18)32157.
    PubMed    


  590. TANDON P, Ismond KP, Riess K, Duarte-Rojo A, et al
    Exercise in Cirrhosis: Translating evidence and experience to practice.
    J Hepatol. 2018 Jun 28. pii: S0168-8278(18)32170.
    PubMed     Abstract available


  591. FUHRMANN V, Krowka M
    Hepatopulmonary syndrome.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)30007.
    PubMed    


  592. QIN JJ, Mao W, Wang X, Sun P, et al
    Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.
    J Hepatol. 2018 Jun 26. pii: S0168-8278(18)32167.
    PubMed     Abstract available


  593. YU JJ, Li JD, Xu XF, Shen F, et al
    Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32061.
    PubMed    


  594. BRADLEY CR, Cox EF, Scott RA, James MW, et al
    Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32122.
    PubMed     Abstract available


  595. TONG M, Che N, Zhou L, Luk ST, et al
    Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32119.
    PubMed     Abstract available


  596. SEGERITZ CP, Rashid ST, Cardoso de Brito M, Paola MS, et al
    hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in alpha1-antitrypsin deficiency.
    J Hepatol. 2018 Jun 4. pii: S0168-8278(18)32113.
    PubMed     Abstract available


  597. TURCO L, Garcia-Tsao G, Rossi R, Villa E, et al
    Reply to "The Relationship of Hyperdynamic Circulation and Cardiodynamic States in Cirrhosis".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32101.
    PubMed    


  598. NAKAMURA K, Zhang M, Kageyama S, Ke B, et al
    Protective effects of heme oxygenase 1 during ischemia r epefrfsuion injury: Hepatocytes or non parenchymal cells?
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32114.
    PubMed    


  599. LEE S, Kang TW
    Reply to "Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32117.
    PubMed    


    May 2018
  600. SUNDARAM V, Goldberg DS, Jalan R
    Author response: Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 May 31. pii: S0168-8278(18)32100.
    PubMed    


  601. MOHKAM K, Rode A, Mabrut JY
    Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma.
    J Hepatol. 2018 May 25. pii: S0168-8278(18)32045.
    PubMed    


  602. PETTA S, Sebastiani G, Bugianesi E, Vigano M, et al
    Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32065.
    PubMed     Abstract available


  603. LE GUILCHER C, Garcin I, Dellis O, Cauchois F, et al
    The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32066.
    PubMed     Abstract available


  604. GUICCIARDI ME, Trussoni CE, Krishnan A, Bronk SF, et al
    Macrophages Contribute to the Pathogenesis of Sclerosing Cholangitis in Mice.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32064.
    PubMed     Abstract available


  605. ALVARADO E, Garcia-Guix M, Mirabet S, Villanueva C, et al
    The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
    J Hepatol. 2018 May 18. pii: S0168-8278(18)32044.
    PubMed    


  606. XU D, Xu M, Kong X, Xia Q, et al
    Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non-parenchymal cells?
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32046.
    PubMed    


  607. NOORDZIJ W, de Jong KP, de Meijer VE
    Response to: Positron emission tomography/computed tomography with (18)F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32024.
    PubMed    


  608. BANERJEE R, Kelly M, Wilman H, Wright T, et al
    Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?
    J Hepatol. 2018 May 16. pii: S0168-8278(18)32033.
    PubMed    


  609. SUAREZ-AMARAN L, Usai C, Di Scala M, Godoy C, et al
    Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-beta induction" [J Hepatol 67 (2017) 669-679].
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32010.
    PubMed    


  610. PATNAIK MM, Kamath PS, Simonetto DA
    Grand Rounds: Hepatic Manifestations of Telomere Biology Disorders.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32052.
    PubMed     Abstract available


  611. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    PubMed     Abstract available


  612. ORRU C, Szydlowska M, Taguchi K, Zavattari P, et al
    Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32056.
    PubMed     Abstract available


  613. OH SH, Swiderska-Syn M, Jewell ML, Premont RT, et al
    Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32054.
    PubMed     Abstract available


    April 2018
  614. CHALAYE J, Costentin CE, Luciani A, Nault JC, et al
    Reply to "PET/CT with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma".
    J Hepatol. 2018 Apr 29. pii: S0168-8278(18)32031.
    PubMed    


  615. MOLLER S, Lee SS
    Cirrhotic cardiomyopathy.
    J Hepatol. 2018 Apr 28. pii: S0168-8278(18)30017.
    PubMed    


  616. EBADI M, Tandon P, Moctezuma-Velazquez C, Ghosh S, et al
    Low Subcutaneous Adiposity Associates with Higher Mortality in Female Patients with Cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32026.
    PubMed     Abstract available


  617. SUNDARAM V, Jalan R, Ahn JC, Charlton MR, et al
    Class III obesity is a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32027.
    PubMed     Abstract available


  618. ZHAO L, Zhang C, Luo X, Wang P, et al
    CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32014.
    PubMed     Abstract available


  619. SPOSITO C, Spreafico C, Mazzaferro V
    Re: validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32016.
    PubMed    


  620. OTETE H, Deleuran T, Fleming KM, Card TR, et al
    Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data.
    J Hepatol. 2018 Apr 16. pii: S0168-8278(18)31978.
    PubMed     Abstract available


  621. WIEST R, Albillos A, Trauner M, Bajaj JS, et al
    Corrigendum to "Targeting the gut-liver axis in liver disease" [J Hepatol 67 (2017) 1084-1103].
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)30149.
    PubMed    



  622. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 10. pii: S0168-8278(18)31966.
    PubMed    



  623. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215.
    PubMed    


  624. LUCIDI C, Lattanzi B, Riggio O, Merli M, et al
    May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
    J Hepatol. 2018 Apr 4. pii: S0168-8278(18)30213.
    PubMed    


  625. VAN VUGT JLA, Alferink LJM, Buettner S, Metselaar HJ, et al
    Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30212.
    PubMed    


  626. BAJAJ JS
    Hepatic encephalopathy: classification and treatment.
    J Hepatol. 2018;68:838-839.
    PubMed    


  627. BEIER JI, Banales JM
    Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications.
    J Hepatol. 2018;68:643-645.
    PubMed    


  628. LEE S, Kim SH
    Reply to: "Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?"
    J Hepatol. 2018;68:863-864.
    PubMed    


  629. HUO TI, Liu PH, Hsu CY
    Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?
    J Hepatol. 2018;68:862-863.
    PubMed    


  630. ATKINSON SR, Way MJ, McQuillin A, Morgan MY, et al
    Reply to: "The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort".
    J Hepatol. 2018;68:860-862.
    PubMed    


  631. BYRNE CD, Perseghin G
    Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?
    J Hepatol. 2018;68:640-642.
    PubMed    


  632. MENDIZABAL M, Silva M
    Acute liver failure: Do the EASL guidelines address the whole spectrum?
    J Hepatol. 2018;68:843.
    PubMed    


    March 2018
  633. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    A Simple Diet- and Chemical-Induced Murine NASH Model with Rapid Progression of Steatohepatitis, Fibrosis and Liver Cancer.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30175.
    PubMed     Abstract available


  634. TURNER AM, Stolk J, Bals R, Lickliter J, et al
    Hepatic-targeted RNA interference provides persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30176.
    PubMed     Abstract available


  635. KONERMAN MA, Jones JC, Harrison SA
    Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].
    J Hepatol. 2018 Mar 19. pii: S0168-8278(18)30150.
    PubMed    


  636. PEREYRA D, Starlinger P
    Intra Platelet Serotonin Affects Overall Survival in Hepatocellular Cancer Patients.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30166.
    PubMed    


  637. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    PubMed     Abstract available


  638. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Abstract available


  639. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Abstract available


  640. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Abstract available


  641. MOSCONI C, Cucchetti A, Pettinato C, Golfieri R, et al
    Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Mar 13. pii: S0168-8278(18)30151.
    PubMed    


  642. ABITBOL S, Dahmani R, Coulouarn C, Ragazzon B, et al
    AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(17)32534.
    PubMed     Abstract available


  643. LEE S, Kang TW, Cha DI, Song KD, et al
    Radiofrequency ablation versus surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30148.
    PubMed     Abstract available


  644. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    PubMed     Abstract available


  645. CHALAYE J, Costentin CE, Luciani A, Amaddeo G, et al
    Positron emission tomography / computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(18)30136.
    PubMed     Abstract available


  646. LIU JJ, Li Y, Chen WS, Liang Y, et al
    Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic beta-Catenin, PIK3CA and MET.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30131.
    PubMed     Abstract available


  647. NAULT JC, Galle PR, Marquardt JU
    The role of molecular enrichment on future therapies in hepatocellular carcinoma.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30134.
    PubMed     Abstract available


  648. KARLSEN TH, Tacke F
    <<The times they are a'changin'>> - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology.
    J Hepatol. 2018 Mar 1. pii: S0168-8278(18)30112.
    PubMed    


  649. LOUVET A, Krag A
    Managing excessive alcohol consumption at a population level: The earlier the better.
    J Hepatol. 2018;68:389-390.
    PubMed    


  650. NAGATA H, Nakagawa M, Asahina Y
    Reply to: "Imaging Basis of AFP and WFA(+)M2BP as Indicators of the risk of HCC after SVR".
    J Hepatol. 2018;68:607-608.
    PubMed    


  651. MAZZEO AT, Maimone S
    Acid-base disorders in liver disease.
    J Hepatol. 2018;68:617-618.
    PubMed    


  652. SCHEINER B, Funk GC
    Reply to: "Acid-base disorders in liver disease".
    J Hepatol. 2018;68:618-619.
    PubMed    


  653. WAZIRY R, Amin J, Law M, Dore GJ, et al
    Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot".
    J Hepatol. 2018;68:616-617.
    PubMed    


  654. WANG XC, Zhang XY, Zhang X, Yuan ZX, et al
    Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm.
    J Hepatol. 2018;68:602-603.
    PubMed    


  655. PETIT JM, Bouillet B, Loffroy R, Rouland A, et al
    Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes.
    J Hepatol. 2018;68:603-604.
    PubMed    


  656. BOURSIER J, de Ledinghen V, Leroy V, Cales P, et al
    Reply to: "Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm" and to "Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes".
    J Hepatol. 2018;68:605-606.
    PubMed    


  657. GALAND J, Ley D, Coopman S, Michaud L, et al
    Primary prophylaxis of oesophageal variceal bleeding in children by ligation is safe and as efficient as secondary prophylaxis.
    J Hepatol. 2018;68:600-601.
    PubMed    


    February 2018
  658. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.
    PubMed    


  659. LYU N, Kong Y, Mu L, Lin Y, et al
    Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma.
    J Hepatol. 2018 Feb 19. pii: S0168-8278(18)30125.
    PubMed     Abstract available


  660. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.
    PubMed    


  661. COENRAAD MJ, Porcher R, Bendtsen F
    Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango.
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30124.
    PubMed     Abstract available


  662. NISHIZAWA N, Ito Y, Eshima K, Ohkubo H, et al
    Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice.
    J Hepatol. 2018 Feb 16. pii: S0168-8278(18)30126.
    PubMed     Abstract available


  663. DUAN F, Wu H, Jia D, Wu W, et al
    O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30119.
    PubMed     Abstract available


  664. ASRANI SK, Saracino G, O'Leary JG, Gonzales S, et al
    Recipient characteristics and morbidity and mortality after liver transplantation.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30120.
    PubMed     Abstract available


  665. ZHANG P, Ge Z, Wang H, Feng W, et al
    Prolactin improves hepatic steatosis via CD36 pathway.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30115.
    PubMed     Abstract available


  666. YOON YI, Song GW, Lee SG, Hwang S, et al
    Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30113.
    PubMed     Abstract available


  667. GUIU B, Jouve JL, Schmitt A, Minello A, et al
    Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30069.
    PubMed     Abstract available


  668. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Abstract available


  669. MOHKAM K, Dumont PN, Manichon AF, Jouvet JC, et al
    No touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30057.
    PubMed     Abstract available


  670. LIM C, Salloum C, Azoulay D
    Reply to Letter: "Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis".
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30067.
    PubMed    


    January 2018
  671. PEI Y, Chen X, Zhang W
    Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis?
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30065.
    PubMed    


  672. BUREAU C, Adebayo D, de Rieu MC, Elkrief L, et al
    Corrigendum to "Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2018 Jan 29. pii: S0168-8278(17)32532.
    PubMed    


  673. YU J, Xu QG, Wang ZG, Yang Y, et al
    Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
    J Hepatol. 2018 Jan 26. pii: S0168-8278(18)30055.
    PubMed     Abstract available


  674. GEHRKE N, Hovelmeyer N, Waisman A, Straub BK, et al
    Hepatocyte-specific deletion of IL1-RI attenuatesliver injury by blocking IL-1 driven autoinflammation.
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30020.
    PubMed     Abstract available


  675. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed    


  676. THIELE M, Rausch V, Fluhr G, Kjaergaard M, et al
    Controlled Attenuation Parameter And Alcoholic Hepatic Steatosis: Diagnostic Accuracy and Role Of Alcohol Detoxification.
    J Hepatol. 2018 Jan 14. pii: S0168-8278(18)30016.
    PubMed     Abstract available


  677. SPREAFICO C, Sposito C, Vaiani M, Cascella T, et al
    Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30010.
    PubMed     Abstract available


  678. ORCI LA, Lacotte S, Delaune V, Slits F, et al
    Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30009.
    PubMed     Abstract available


  679. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Abstract available


  680. TURCO L, Garcia-Tsao G, Magnani I, Bianchini M, et al
    Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30011.
    PubMed     Abstract available


  681. THOMAS JA, Ramachandran P, Forbes SJ
    Studies of macrophage therapy for cirrhosis - from mice to men.
    J Hepatol. 2018 Jan 6. pii: S0168-8278(18)30002.
    PubMed    


    December 2017
  682. UTOH R, Komori J, Kuge H, Tatsumi K, et al
    Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney.
    J Hepatol. 2017 Dec 26. pii: S0168-8278(17)32531.
    PubMed     Abstract available


  683. XU B, Jiang M, Chu Y, Wang W, et al
    Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32494.
    PubMed     Abstract available


  684. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    PubMed     Abstract available


  685. CALDWELL S, Marchesini G
    Cryptogenic vs NASH-cirrhosis: The rose exists well before its name.
    J Hepatol. 2017 Dec 13. pii: S0168-8278(17)32488.
    PubMed    


  686. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed    


  687. RATZIU V
    A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481.
    PubMed     Abstract available


  688. VAN VUGT JLA, Alferink LJM, Buettner S, Gaspersz MP, et al
    A Model including Sarcopenia Surpasses the MELD Score in Predicting Waiting List Mortality in Cirrhotic Liver Transplant Candidates.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32474.
    PubMed     Abstract available


    November 2017
  689. LAU HH, Ng NHJ, Loo LSW, Jasmen J, et al
    The molecular functions of hepatocyte nuclear factors in and beyond the liver.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32451.
    PubMed     Abstract available


  690. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Abstract available


  691. NOBILI V, Mosca A, Scorletti E, Byrne CD, et al
    Reply 'Energy drinks and risk of non alcoholic steatohepatitis'.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32446.
    PubMed    


  692. ROBIN S, Buchanan R, Poole R
    Energy drinks and adolescents - a hepatic health hazard?
    J Hepatol. 2017 Nov 22. pii: S0168-8278(17)32444.
    PubMed    


  693. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Abstract available


  694. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Abstract available


  695. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Abstract available


  696. SCHLEGEL A, Kalisvaart M, Scalera I, Laing RW, et al
    The UK-DCD-Risk-Score: a new proposal to define futility in Donation after Circulatory Death liver transplantation.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32432.
    PubMed     Abstract available


  697. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Abstract available


  698. LINECKER M, Krones T, Berg T, Niemann CU, et al
    Potentially Inappropriate Liver Transplantation in the Era of the "Sickest-first" Policy - A Search for the Upper Limits.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32430.
    PubMed     Abstract available


  699. HU C, Li W, Tian F, Jiang K, et al
    Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409.
    PubMed     Abstract available


  700. HAYES P, Mookerjee RP
    Early TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32410.
    PubMed    


    October 2017
  701. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    PubMed    


  702. ASHHAB AA, Rodin H, Debes JD
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant-Authors-reply.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32404.
    PubMed    


  703. CHOUDHARY NS, Saraf N, Soin AS
    Liver Transplantation for Grade 3 Acute on Chronic Liver Failure: Type of Organ Failure is Important.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32401.
    PubMed    


  704. ARTRU F, Louvet A
    Reply to <<Liver transplantation for grade 3 acute-on-chronic liver failure: type of organ failure is important>>.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32402.
    PubMed    


  705. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Abstract available


  706. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Abstract available


  707. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    PubMed     Abstract available


  708. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    PubMed     Abstract available


  709. JACKSON R, Psarelli EE, Berhane S, Johnson PJ, et al
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32389.
    PubMed    


  710. BRUIX J, Cheng AL, Llovet J
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32392.
    PubMed    


  711. NAULT JC, Sutter O, Nahon P, Ganne-Carrie N, et al
    Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations.
    J Hepatol. 2017 Oct 12. pii: S0168-8278(17)32351.
    PubMed     Abstract available


  712. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed    


  713. FUJIWARA N, Friedman SL, Goossens N, Hoshida Y, et al
    Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32328.
    PubMed     Abstract available


  714. LIM C, Bhangui P, Salloum C, Gavara CG, et al
    Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32331.
    PubMed     Abstract available


  715. GUSTOT T, Agarwal B
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation.
    J Hepatol. 2017;67:667-668.
    PubMed    


    September 2017
  716. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    PubMed    


  717. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    PubMed    


  718. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Reply to Letters to the Editor from Mazzarelli et al. entitled "Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything" and Tammineedi et al. entitled "More extended indication of DAA therapy in p
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292.
    PubMed    


  719. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Abstract available


  720. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed    


  721. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32207.
    PubMed    


  722. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed    


  723. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed    


  724. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Abstract available


  725. WANG X, Mao W, Fang C, Tian S, et al
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32275.
    PubMed     Abstract available


  726. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed    


  727. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed    


  728. URBAN SK, Krawczyk M, Willms A, Sanger H, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32262.
    PubMed    


  729. MAZZARELLI C, Cannon MD, Belli LS, Agarwal K, et al
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32265.
    PubMed    


  730. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed    


  731. WANG J, Yu Y, Li G, Shen C, et al
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32261.
    PubMed     Abstract available


  732. WANG M, Shen G, Xu L, Liu X, et al
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-kappaB activation in hepatic macrophages.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32263.
    PubMed     Abstract available


  733. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed    


  734. PONZIANI FR, Giarretta I, Nicoletti A, Gatto I, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32257.
    PubMed    


  735. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Abstract available


    August 2017
  736. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Abstract available


  737. TORRECILLA S, Sia D, Harrington AN, Zhang Z, et al
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32252.
    PubMed     Abstract available


  738. CHIANG DY, Villanueva A
    Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation?
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32210.
    PubMed    


  739. PETTA S, Marchesini G
    Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    J Hepatol. 2017 Aug 16. pii: S0168-8278(17)32186.
    PubMed    


  740. REBOUISSOU S, Zucman-Rossi J, Moreau R, Qiu Z, et al
    Note of caution: contaminations of hepatocellular cell lines.
    J Hepatol. 2017 Aug 11. pii: S0168-8278(17)32206.
    PubMed    


  741. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed    


  742. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Abstract available


  743. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Abstract available


  744. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed    


  745. SEBASTIAN M, Johannes M
    Is Room Temperature Susceptometry really an accurate method to assess hepatocellular iron? A response.
    J Hepatol. 2017 Aug 7. pii: S0168-8278(17)32192.
    PubMed    


  746. PAISANT A, Laine F, Gandon Y, Bardou-Jacquet E, et al
    Is Room Temperature Susceptometer really an accurate method to assess hepatocellular iron?
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32193.
    PubMed    


  747. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed    


  748. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed    


    July 2017
  749. LEE S, Kim SH
    Reply to: "How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma".
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32156.
    PubMed    


  750. XU XF, Yu JJ, Xing H, Shen F, et al
    How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32157.
    PubMed    


  751. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Abstract available


  752. LEE WM
    Public Health: Acetaminophen (APAP) Hepatotoxicity- Isn't It Time for APAP to Go Away?
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32148.
    PubMed     Abstract available


  753. NAULT JC, Paradis V, Cherqui D, Vilgrain V, et al
    Molecular classification of hepatocellular adenoma in clinical practice.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32152.
    PubMed     Abstract available


  754. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Abstract available


  755. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Abstract available


  756. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed    


  757. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Abstract available


  758. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Abstract available


  759. GAVRIILIDIS P, Roberts KJ, Askari A, Sutcliffe RP, et al
    Evaluation of the Current Guidelines for Resection of hepatocellular carcinoma Using the Appraisal of Guidelines Research and Evaluation II Instrument.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32136.
    PubMed     Abstract available


  760. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed    


  761. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed    


  762. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies.
    J Hepatol. 2017 Jul 4. pii: S0168-8278(17)32134.
    PubMed     Abstract available


  763. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Abstract available


    June 2017
  764. BECK M, Schirmacher P, Singer S
    Alterations of the nuclear transport system in hepatocellular carcinoma - new basis for therapeutic strategies.
    J Hepatol. 2017 Jun 30. pii: S0168-8278(17)32122.
    PubMed     Abstract available


  765. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Abstract available


  766. MARIN V, Poulsen K, Odena G, McMullen MR, et al
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32086.
    PubMed     Abstract available


  767. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed    


  768. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Abstract available


  769. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Abstract available


  770. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    RE: Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32084.
    PubMed    


  771. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed    


  772. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed    


  773. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed    


  774. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Abstract available


  775. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed    


    May 2017
  776. TERATANI T, Tomita K, Suzuki T, Furuhashi H, et al
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling.
    J Hepatol. 2017 May 26. pii: S0168-8278(17)32056.
    PubMed     Abstract available


  777. LU Z, Zuo B, Jing R, Gao X, et al
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    J Hepatol. 2017 May 23. pii: S0168-8278(17)32055.
    PubMed     Abstract available


  778. CALDERARO J, Couchy G, Imbeaud S, Amaddeo G, et al
    Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification.
    J Hepatol. 2017 May 19. pii: S0168-8278(17)32050.
    PubMed     Abstract available


  779. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Abstract available


  780. DE GALARRETA MR, Lujambio A
    Therapeutic editing of hepatocyte genome in vivo.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32048.
    PubMed     Abstract available


  781. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed    


  782. WANG Q, Lv Y, Bai M, Wang Z, et al
    Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    J Hepatol. 2017 May 12. pii: S0168-8278(17)32015.
    PubMed     Abstract available


  783. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.
    J Hepatol. 2017 May 10. pii: S0168-8278(17)32012.
    PubMed    


  784. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed    


  785. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed    


  786. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Abstract available


  787. LEE S, Kim SH, Lee JE, Sinn DH, et al
    Preoperative Gadoxetic acid-enhanced MRI for Predicting Microvascular Invasion in Patients with Single hepatocellular carcinoma.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32005.
    PubMed     Abstract available


  788. MUELLER J, Raisi H, Rausch V, Peccerella T, et al
    Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32000.
    PubMed     Abstract available


  789. NADIM MK, DiNorcia J, Ji L, Groshen S, et al
    Inequity In Organ Allocation For Patients Awaiting Liver Transplantation: Rationale for Uncapping the Model for End-Stage Liver Disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32003.
    PubMed     Abstract available


  790. VAUTHEY JN, Mizuno T, Overman MJ, Soubrane O, et al
    Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
    J Hepatol. 2017 May 2. pii: S0168-8278(17)30252.
    PubMed    


  791. MOSCA A, Nobili V, De Vito R, Crudele A, et al
    Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
    J Hepatol. 2017;66:1031-1036.
    PubMed     Abstract available


  792. SANDBOTHE M, Buurman R, Reich N, Greiwe L, et al
    The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4.
    J Hepatol. 2017;66:1012-1021.
    PubMed     Abstract available


  793. KARLAS T, Petroff D, Sasso M, Fan JG, et al
    Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    J Hepatol. 2017;66:1022-1030.
    PubMed     Abstract available


  794. HUANG K, Du M, Tan X, Yang L, et al
    PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    J Hepatol. 2017;66:962-977.
    PubMed     Abstract available


    April 2017
  795. KLINGENBERG M, Matsuda A, Diederichs S, Patel T, et al
    Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30250.
    PubMed     Abstract available


  796. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed    


  797. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed    


  798. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Abstract available


  799. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Abstract available


  800. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Abstract available


  801. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed    


  802. CARUSO S, Calderaro J, Letouze E, Nault JC, et al
    Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    J Hepatol. 2017;66:734-742.
    PubMed     Abstract available


  803. KOPEC AK, Joshi N, Cline-Fedewa H, Wojcicki AV, et al
    Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of Mmp12.
    J Hepatol. 2017;66:787-797.
    PubMed     Abstract available


  804. WOOLBRIGHT BL, Jaeschke H
    Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.
    J Hepatol. 2017;66:836-848.
    PubMed     Abstract available


  805. FERRERE G, Wrzosek L, Cailleux F, Turpin W, et al
    Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    J Hepatol. 2017;66:806-815.
    PubMed     Abstract available


    March 2017
  806. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    PubMed     Abstract available


  807. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    PubMed    


  808. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    PubMed    


  809. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Abstract available


  810. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Abstract available


  811. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    PubMed     Abstract available


  812. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    PubMed     Abstract available


  813. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    PubMed     Abstract available


  814. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    PubMed     Abstract available


  815. JOSHI D, Gupta N, Samyn M, Deheragoda M, et al
    The management of childhood liver diseases in adulthood.
    J Hepatol. 2017;66:631-644.
    PubMed     Abstract available


  816. LACKNER C, Spindelboeck W, Haybaeck J, Douschan P, et al
    Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
    J Hepatol. 2017;66:610-618.
    PubMed     Abstract available


  817. RAMIREZ T, Li YM, Yin S, Xu MJ, et al
    Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.
    J Hepatol. 2017;66:601-609.
    PubMed     Abstract available


  818. LUKACS-KORNEK V, Lammert F
    The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.
    J Hepatol. 2017;66:619-630.
    PubMed     Abstract available


  819. SPIRLI C, Mariotti V, Villani A, Fabris L, et al
    Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    J Hepatol. 2017;66:571-580.
    PubMed     Abstract available


  820. LANGIEWICZ M, Schlegel A, Saponara E, Linecker M, et al
    Hedgehog pathway mediates early acceleration of liver regeneration induced by a novel two-staged hepatectomy in mice.
    J Hepatol. 2017;66:560-570.
    PubMed     Abstract available


    February 2017
  821. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Abstract available


  822. TREBICKA J
    Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?
    J Hepatol. 2017;66:442-450.
    PubMed     Abstract available


  823. MA J, Hwang SJ, Pedley A, Massaro JM, et al
    Bi-directional analysis between fatty liver and cardiovascular disease risk factors.
    J Hepatol. 2017;66:390-397.
    PubMed     Abstract available


  824. TAPPER EB, Saini SD, Sengupta N
    Extensive testing or focused testing of patients with elevated liver enzymes.
    J Hepatol. 2017;66:313-319.
    PubMed     Abstract available


    January 2017
  825. HASHIDA R, Kawaguchi T, Bekki M, Omoto M, et al
    Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review.
    J Hepatol. 2017;66:142-152.
    PubMed     Abstract available


  826. STICKEL F, Moreno C, Hampe J, Morgan MY, et al
    The genetics of alcohol dependence and alcohol-related liver disease.
    J Hepatol. 2017;66:195-211.
    PubMed     Abstract available


  827. GARIANI K, Ryu D, Menzies KJ, Yi HS, et al
    Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
    J Hepatol. 2017;66:132-141.
    PubMed     Abstract available


  828. GUIXE-MUNTET S, de Mesquita FC, Vila S, Hernandez-Gea V, et al
    Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury.
    J Hepatol. 2017;66:86-94.
    PubMed     Abstract available


  829. POISSON J, Lemoinne S, Boulanger C, Durand F, et al
    Liver sinusoidal endothelial cells: Physiology and role in liver diseases.
    J Hepatol. 2017;66:212-227.
    PubMed     Abstract available


  830. HOCQUELET A, Aube C, Rode A, Cartier V, et al
    Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.
    J Hepatol. 2017;66:67-74.
    PubMed     Abstract available


    December 2016
  831. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed    


  832. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed    


  833. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed    


    November 2016
  834. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed    


    October 2016
  835. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed    


  836. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed    


    September 2016
  837. FUCHS CD, Paumgartner G, Wahlstrom A, Schwabl P, et al
    Metabolic Preconditioning Protects BSEP/ABCB11-/- Mice against Cholestatic Liver Injury.
    J Hepatol. 2016 Sep 1. pii: S0168-8278(16)30482.
    PubMed     Abstract available


    July 2016
  838. PAIS R, Sidney Barritt A 4th, Calmus Y, Scatton O, et al
    Nafld and liver transplantation: current burden and expected challenges.
    J Hepatol. 2016 Jul 30. pii: S0168-8278(16)30403.
    PubMed     Abstract available


    May 2016
  839. VERKADE HJ, Bezerra JA, Davenport M, Schreiber RA, et al
    Biliary atresia and other cholestatic childhood diseases: advances and future challenges.
    J Hepatol. 2016 May 6. pii: S0168-8278(16)30186.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: